Clinical trial Recruiting at 1 site Observational Ages 18 and up

Real-world registry of renal denervation for adults with high blood pressure in France

Official title: FRiEND Registry: Real Life Data From Hypertensive Patients Treated With Renal Denervation in Current Practice in France- French RENal Denervation Registry

Run by University Hospital, Grenoble · NCT07206030 · Data updated 2026-11-12

This registry will collect information from adults in France who have had renal denervation to see if it controls high blood pressure and to track safety.

More Hypertension (HTN) trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorUniversity Hospital, Grenoble
Academic / other
Locations1 site (La Tronche, France)
StatusRecruiting
StartedJune 23, 2025
Main results expectedApril 2028
Study endsOctober 2028
Registry record updatedOctober 3, 2025
Trial IDNCT07206030 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (over 18) with hypertension treated with renal denervation in France, including patients treated in the past or those who will undergo the procedure, are eligible.

Probably not a fit

Patients who were not offered renal denervation, who refuse data collection, or who were treated outside France are unlikely to benefit from participating in this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Coordinated by Grenoble University Hospital, this national registry aims to compile exhaustive data on patients treated with renal denervation in France, including procedures performed since January 2010 and those performed prospectively after March 2025. The registry accepts all catheter types and includes cases from routine care, transitional reimbursement programs, industry registries, and randomized trials. Data collected will include patient demographics, procedural details, blood pressure outcomes, medications, and adverse events during follow-up to characterize effectiveness and safety in routine practice. The goal is to describe who receives the procedure in France and how it performs across different devices and care settings.

Why it matters

Potential benefit: If successful, the registry could clarify which patients benefit most from renal denervation, improve safety understanding, and inform clinical and reimbursement decisions in France.

How similar studies have gone: Randomized trials have shown that renal denervation can lower blood pressure and current guidelines include the technique, but comprehensive national real-world registries remain relatively limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult ( \> 18 years old) hypertensive patients treated with RDN in France whatever the catheter and the indication. This might include retrospective data for patient already treated with RDN in the past.

Exclusion Criteria:

* RDN not proposed to the patient, patient opposing the collection and use of his/her data for research purposes.

Where it's running

  • Chu Grenoble Alpes
    La Tronche, France, France
    Recruiting

Study contacts

  • Principal investigator: Olivier ORMEZZANO, Doctor of medicine — University Hospital, Grenoble
  • Study coordinator: Olivier ORMEZZANO, Doctor of medicine
  • Email: oormezzano@chu-grenoble.fr
  • Phone: +33476768888

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.